Immunomodulation and antitumor activity of a mushroom product, proflamin, isolated from Flammulina velutipes (W. Curt.: Fr.) singer (agaricomycetideae)

International Journal of Medicinal Mushrooms

Volumn 9, Issue 2, 2007, Pages 109-122

  Maruyama, Hirofumi ^a   Ikekawa, Tetsuro ^a  

^a Japanese Association for Integrative Medicine   (Japan)

Author keywords

Antitumor effect; Cellular immunity; Combination therapy; EA6; Flammulina velutipes; Humoral immunity; Immunopotentiator; Macrophage; Medicinal mushrooms; Proflamin; Protein bound polysaccharide

Indexed keywords

ALANINE; AMINO ACID; ANTINEOPLASTIC AGENT; ARGININE; ASPARTIC ACID; CANCER VACCINE; CARBOHYDRATE; CONCANAVALIN A; GLUTAMIC ACID; GLUTARALDEHYDE; GLYCINE; GLYCOPROTEIN; HISTIDINE; ISOLEUCINE; LEUCINE; LYSINE; LYSOZYME; METHIONINE; PHENYLALANINE; PLANT EXTRACT; POLYSACCHARIDE; PROFLAMIN; PROLINE; SERINE; THREONINE; THYROXINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYOSURGERY; DELAYED HYPERSENSITIVITY; DRUG ACTIVITY; DRUG ISOLATION; ENZYME ACTIVITY; FIBROSARCOMA; FLAMMULINA VELUTIPES; HUMORAL IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; LEWIS CARCINOMA; LYMPHOCYTE; LYMPHOCYTE TRANSFORMATION; MELANOMA B16; MOLECULAR WEIGHT; MOUSE; MUSHROOM; NONHUMAN; OPTIMAL DRUG DOSE; PERITONEUM CELL; PHAGOCYTOSIS; SARCOMA; SOLID TUMOR; TUMOR GROWTH;

BASIDIOMYCOTA; FLAMMULINA VELUTIPES; MUS;

EID: 34347328146     PISSN: 15219437     EISSN: None     Source Type: Journal    
DOI: 10.1615/IntJMedMushr.v9.i2.20     Document Type: Article

References (29)

1. Ablin R. J., Soanes W. A., and Gonder M. J. 1971. Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate. Cryobiology, 8, 271-279.
2. Chihara G. 1984. Immunomodulation agents and their mechanism. In: Lentinan, Fenichel, ed., Marcel Dekker, New York, 409 pp.
3. Chihara G. 1988. Current status and possible future of antitumor drugs with special reference to pharmacology of oriental medicine. Yakugaku Zasshi, 108, 171-186.
4. Cunningham A. J. and Szenberg A. 1968. Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology, 14, 599-601.
5. Hanna M. G. and Peters L. C. 1978. BCG immunotherapy: efficacy on BCG-induced tumor immunity in guinea pigs with regional tumor and/or visceral micrometastases. In: Immunotherapy of Human Cancer, Hersh, E., ed., Raven Press, New York, pp. 111-129.
6. Hara M. and Hanaoka T. 2005. An epidemiological study on relationship between decrease of cancer death rate and agricultural products. Noukouken Tsushin, 1, 2-6.
7. Hara M., Hanaoka T., Kobayashi M., Otani T., Adachi H. Y., Montani A., Natsukawa S., Shaura K., Koizumi Y., Kasuga Y., Matsuzawa T., Ikekawa T., Sasaki S., and Tsugane S. 2003. Cruciferous vegetables, mushrooms, and gastrointestinal cancer risks in a multicenter, hospital-based case-control study in Japan. Nutr Cancer, 46, 138-147.
8. Ikekawa T. 2000. On biological activity of mushrooms. Biotherapy, 14, 945-951.
9. Ikekawa T. 2001. Beneficial effects of edible and medicinal mushrooms on health care. Int J Med Mushr, 3, 291-298.
10. Ikekawa T. 2005. Cancer risk reduction by intake of mushrooms and clinical studies on EEM. Presented at 3rd International Medicinal Mushrooms Conference, Port Townsend, WA, Oct. 12-17. Int J Med Mushr, 7, 347.
11. Ikekawa T., Ikeda Y., Yoshioka Y., Nakanishi K., Yokoyama E., and Yamazaki E. 1982. Studies on antitumor polysaccharides of Flammulina velutipes (Curt. ex Fr.) Sing. II. The structure of EA3 and further purification of EA5. J Pharmacobiogyn, 5, 576-581.
12. Ikekawa T., Maruyama H., Miyano T., Okura A., Kawasaki Y., Naito K., Kawamura K., and Shiratori K. 1985. Proflamin, a new antitumor agent: preparation, physicochemical properties and antitumor activity. Jpn J Cancer Res (Gann), 76, 142-148.
13. Ikekawa T., Maruyama H., Sayama K., and Yoshida M. 2002. Antitumor activity and immunopotentiation of EA6 isolated from Flammulina velutipes. Jpn J Cancer Res, 93 (Suppl.), 454 pp.
14. Ikekawa T., Nakanishi M., Uehara N., Chihara G., and Fukuoka F. 1968. Antitumor action of some Basidiomycetes, especially Phellinus linteus. Jpn J Cancer Res (Gann), 59, 155-157.
15. Ikekawa T., Uehara N., Maeda Y., Nakanishi M., and Fukuoka F. 1969. Antitumor activity of aqueous extracts of edible mushrooms. Cancer Res, 29, 734-735.
16. Ikekawa T., Yosioka Y., Emori M., Sano T., and Fukuoka F. 1973. Studies on antitumor activity of polysaccharides from Flammulina velutipes (Curt. ex Fr.) Sing. Cancer Chemother Rep (Part 1), 57, 85-86.
17. Maruyama H. and Ikekawa T. 2005a. Antitumor effect of combination therapy of proflamin with cryosurgery of Meth-A fibrosarcoma in BALB/c mice. Int J Med Mushr, 7, 561-567.
18. Maruyama H. and Ikekawa T. 2005b. Combination therapy of transplanted Meth-A fibrosarcoma in BALB/c mice with protein-bound polysaccharide EA6 isolated from enokitake mushroom Flammulina velutipes (W. Curt.: Fr.) Singer and surgical excision. Int J Med Mushr, 7, 213-220.
19. Maruyama H., Murofushi S., and Ikekawa T. 1985. Antitumor effect of combined treatment with PRF and surgical excision. The 105th Annual Meeting of the Pharmaceutical Society of Japan, p. 534.
20. Nowotny A., Abdelnoor A., Behling U. H., Butler R. C., Johnson A. G., and Nowotny A. M. 1982. Molecular aspects of the adjuvant and the other beneficial effects of endotoxins. In: Immunomodulation by Microbial Products and Related Synthetic Compound. Yamaura Y., Kotani S., Azuma I., Koda A., and Shiba T., eds., Excerpta Medica, Amsterdam, pp. 103-116.
21. Ohkuma T., Otagiri K., Ikekawa T., and Tanaka S. 1982. Augmentation of antitumor activity by combined cryo-destruction of Sarcoma 180 and protein-bound polysaccharide, EA6, isolated from Flammulina velutipes (Curt. ex Fr.) Sing. in ICR mice. J Pharmacobiodyn, 5, 439-444.
22. Ohkuma T., Tanaka S., and Ikekawa T. 1983. Augmentation of host's immunity by combined cryodestruction of Sarcoma 180 and administration of protein-bound polysaccharide, EA6, isolated from Flammulina velutipes (Curt. ex Fr.) Sing. in ICR mice. J Pharmacobiodyn, 6, 88-95.
23. Okura A., Sawasaki Y., Naito K., Yoshida E., Arakawa H., and Ikekawa T. 1983. Immunomodulation of a new antitumor agent, proflamin (PRF). Proceedings of the Japanese Cancer Association. The 42nd Annual Meeting, 125 pp.
24. Otagiri K. 1989a. Twenty-year study on antitumor activities of mushrooms. In: Immunomodification of EA6 and PRF. Nagano Prefecture Agricultural Technology Institute, ed., Nagano, Japan, pp. 51-52.
25. Otagiri K. 1989b. Twenty-year study on antitumor activities of mushrooms. In: Epidemiological Study on intake of Flammulina velutipes, Nagano Prefecture Agricultural Technology Institute, ed., Nagano, Japan, pp. 56-63.
26. Otagiri K. 1989c. Twenty-year study on antitumor activities of mushrooms. In: Studies on Prevention of Carcinogenesis of Flammulina velutipes (I). Decrease of Cancer Death Rate by Intake of Flammulina velutipes, Nagano Prefecture Agricultural Technology Institute, ed., Nagano, Japan, pp. 75-79.
27. Otagiri K., Ohkuma T., Ikekawa T., and Tanaka S. 1983. Intensification of antitumor-immunity by protein-bound polysaccharide, EA6, derived from Flammulina velutipes (Curt. ex Fr.) Sing. combined with murine Leukemia L1210 vaccine in animal experiments. J Pharmacobiodyn, 6, 96-104.
28. Tanaka S. 1982. Immunological aspects of cryosurgery in general surgery. Cryobiology, 19, 257-272.
29. Yoshioka Y., Sano T., and Ikekawa T. 1973. Studies on antitumor polysaccharides of Flammulina velutipes (Curt. ex Fr.) Sing. I. Chem Pharm Bull, 21, 1772-1776.